Comparison of kidney transplantation outcomes in patient with Hepatitis C achieving Rapid Viral Response versus Complete Early Viral Response

Hepatitis C in Kidney Transplant Patients

Abstract

Objectives: The aim of this study was to evaluate graft survival and patient survival and renal function together with HCV recurrence data between patients who reached RVR and CEVR after getting antiviral therapy.

Study Design: It was a cross-sectional study.

Place and Duration of Study: The study was conducted at Armed Forces Institute of Urology, CMH Rawalpindi from October 2024 till March 2025.

Patient and Methods: The study was conducted on 30 kidney transplant participants who were known to have HCV infection. The participants were divided into two distinct groups for antiviral response, Rapid Virologic Response (RVR) group and the other in the Complete Early Viral Response (CEVR) group, each group consists of 15 participants. Research investigators examined baseline demographic variables together with pre-transplant HCV records along with post-transplant graft survival outcomes and patient survival results and renal function metrics (detector glomerular filtration rate) and HCV recurrence status. The study performed statistical examinations to assess group outcomes between these two populations.

Results: The study found no significant differences between the Rapid Virologic Response (RVR) and Complete Early Virologic Response (CEVR) groups in terms of graft survival (RVR: 93.3%, CEVR: 86.7%; p=0.51), HCV recurrence (RVR: 6.7%, CEVR: 13.3%; p=0.56), renal function (RVR: 54.6 ± 9.8, CEVR: 53.9 ± 10.2; p=0.85).

Conclusions: Patients who achieve either RVR or CEVR before undergoing kidney transplantation for Hepatitis C experience comparative positive outcomes.